Clinical trial
Becotatug Vedotin Combined With Tislelizumab and Low-Dose Lenvatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma Who Failed First-Line Therapy: A Phase II Exploratory Study
NCT07686926 is registered in ClinicalTrials.gov with Tianjin Medical University Cancer Institute and Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Becotatug Vedotin Combined With Tislelizumab and Low-Dose Lenvatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma Who Failed First-Line Therapy: A Phase II Exploratory Study
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- August 1, 2026
- Completion date
- December 31, 2029
- Enrollment
- 36 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.